跳至主要内容
临床试验/NCT00681967
NCT00681967已完成1 期

Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial

AstraZeneca1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2004年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
AstraZeneca
入组人数
30
试验地点
1
主要终点
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa

研究概览

简要总结

To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent
  • Age over 18 years
  • Histologically proven squamous cell cancer of the head & neck (SCCHN)
  • Indication for postoperative Radiotherapy: pT3, pT4, pN2b, pN2c, pN3

排除标准

  • Hypersensitivity to ZD1839 or any of the excipients of this product
  • Tumour stage M1
  • Co-existing malignancies diagnosed within the last 5 years. Exceptions: basal cell carcinoma, cervical cancer in situ
  • Absolute neutrophil counts <1.5 x 109

研究组 & 干预措施

Cohort 1

Experimental

post operative combination of gefinib and RT

干预措施: Gefitinib (Drug)

Cohort 2

Experimental

combination of gefitinib with RT and Chemotherapy in non operated patients

干预措施: Gefitinib (Drug)

结局指标

主要结局

To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa

次要结局

  • Both cohorts overall survival (OS) local control (LC) rate at six months and at one year
  • Cohort 1 only time-to-recurrence (TTR)
  • Cohort 2 only time-to-progression (TTP). Complete Response (CR) rate time to treatment failure (TTF)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验